Fig. 3.

Treatment with IL-12-LNP confers a significant survival advantage on HCC-bearing mice independently of MYC. a Kaplan-Meier survival analysis comparing overall survival (OS) between control (NST-LNP, n = 15), and IL-12-treated (IL-12-LNP, n = 14) MYC-driven HCC mice. P-values were calculated using log-rank test. P values: ** p < 0.01. b Morphology of livers isolated from control (NST-LNP, n = 15) and IL-12-treated (IL-12-LNP, n = 14) HCC mice at the end of treatment schedule. Two representative images are shown from each group of mice. c Hematoxylin & Eosin (H&E) analysis of liver tumors isolated from control (NST-LNP, n = 7) and IL-12 treated (IL-12-LNP, n = 7) HCC-bearing mice at the end of treatment. d-e Immunohistochemistry for transgenic hMYC protein in liver tumor (d), and surrounding normal liver (e) tissues isolated from control (NST-LNP, n = 7) and IL-12 treated (IL-12-LNP, n = 7) MYC-driven HCC mice. One representative image is shown from each group of mice. Scale bars = 50 μm